By
From the * Cell and Molecular Biology Graduate Group and the Department of Medicine, Cancer
Center, and Institute for Human Gene Therapy, School of Medicine, University of Pennsylvania,
Philadelphia, Pennsylvania 19104; the § School of Veterinary Medicine, University of Pennsylvania,
Philadelphia, Pennsylvania 19104; and
The Wistar Institute, Philadelphia, Pennsylvania 19104
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Recombinant interleukin 12 (IL-12) can profoundly suppress cellular immune responses in
mice. To define the underlying mechanism, recombinant murine (rm)IL-12 was given to
C57BL/6 mice undergoing alloimmunization and found to transiently but profoundly suppress in vivo and in vitro allogeneic responses and in vitro splenocyte mitogenic responses. Use of
neutralizing antibodies and genetically deficient mice showed that IFN- (but not TNF-
)
mediated rmIL-12-induced immune suppression. Splenocyte fractionation studies revealed that
adherent cells from rmIL-12-treated mice suppressed the mitogenic response of normal nonadherent cells to concanavalin A and IL-2. Addition of an inhibitor of nitric oxide synthase
(NOS) restored mitogenic responses, and inducible (i)NOS
/
mice were not immunosuppressed by rmIL-12. These results support the view that suppression of T cell responses is due
to NO produced by macrophages responding to the high levels of IFN-
induced by rmIL-12.
When a NOS inhibitor was given with rmIL-12 during vaccination of A/J mice with irradiated SCK tumor cells, immunosuppression was averted and the extent of rmIL-12's ability to
enhance induction of protective antitumor immunity was revealed. This demonstrates that
rmIL-12 is an effective vaccine adjuvant whose efficacy may be masked by its transient immunosuppressive effect.
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Interleukin (IL)-12 is an immunoregulatory cytokine with
potent antitumor, antiviral, and antimicrobial effects (1, 2). Many of its activities are attributable to its ability to induce Th1 CD4+ T cell differentiation, CD8+ T cell cytotoxicity,
and NK cell activation. IL-12 is proinflammatory through its
ability to induce production of IFN-, TNF-
, GM-CSF, and other cytokines by T and NK cells. A particularly important mediator of IL-12 effect is IFN-
, which, among
other actions, activates macrophages and induces the production of nitric oxide (NO).1 IFN-
also acts on many
other types of cells, including tumor cells, and its ability to
upregulate MHC expression, slow cell proliferation, and
inhibit angiogenesis (3) may contribute to IL-12's antitumor effects.
Therapeutic use of rIL-12 can be accompanied by severe
toxicities. Dose- and schedule-dependent toxicities have
been seen during clinical trials (6, 7) and in mice (8). Administration of recombinant murine (rm)IL-12 during lymphocytic choriomeningitis virus (LCMV) infection in mice
has been associated with adverse immunological effects
manifest by higher viral loads, decreased antiviral CTL activity, and poorer outcome (9). While studying the effects
of rmIL-12 during vaccination with genetically modified tumor cells, we identified a dose-dependent transient suppression of the immune response that was accompanied by
suppressed in vitro splenocyte responses to T cell mitogens
(10). These effects of high-dose rmIL-12 were generalized,
affecting responses to allogeneic vaccination and splenocyte
mitogenic responses in naive mice of many strains, and
appeared to result from impairment of immune effector
function rather than failure to induce immunity. Studies
described in this manuscript examine the mechanism of rmIL-12 immune suppression that appears to result from
inhibition of T cell proliferation by NO generated by macrophages activated by the IFN- produced in response to
rmIL-12. When inhibitors of NO generation were given
with rmIL-12 during vaccination, it prevented immune
suppression and allowed the potent vaccine adjuvant effect
of rmIL-12 to be fully revealed.
![]() |
Materials and Methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Mice and Cell Lines.
5-8-wk-old female C57BL/6 (H-2b) mice were purchased from Harlan-Sprague-Dawley (Indianapolis, IN). IFN-Immunization and Challenge.
Immunization of C57BL/6 mice with HKB cells or A/J mice with SCK or SCK.GM cells was performed with cells suspended in PBS at 107 trypan blue- excluding cells/ml. Cells were irradiated with 6,000 rads from a 137Cs source, and mice were vaccinated with 106 cells subcutaneously (day 0). Mice given rmIL-12 (Genetics Institute, Andover, MA) were injected intraperitoneally with 500 ng/day (all strains except A/J) or 250 ng/day (A/J strain) on days 0-4 and 7-11 (10 injections) unless otherwise noted, whereas control mice received PBS injections. Where indicated, vaccinated mice received 1 mg of anti-IFN-Mitogen and Alloantigen Stimulation of Splenocytes.
In vitro mitogenic stimulation of splenocytes with 2.5 µg/ml Con A or 100 U/ml rmIL-2 was performed as previously described (10). Proliferative responses to allogeneic antigens (MLR) were measured when splenocytes were stimulated with 105 mitomycin C-treated A/J splenocytes. Splenocyte fractionation was performed by allowing 105 splenocytes to adhere for 90 min in 96-well plates after which the nonadherent cells were removed and cocultured with adherent cells from different wells for assay. When added, antibodies (XMG6 for IFN-Delayed Type Hypersensitivity Assessment.
For assessment of allogeneic delayed type hypersensitivity (DTH) responses, mice were injected with 50 µl PBS containing 106 irradiated SCK cells in the right footpad and with 50 µl PBS in the left footpad. Footpad thickness measurements were taken just before injection and 24 h later using a Starrett pocket gauge (Athol, MA). Data are presented as the difference in footpad swelling induced by SCK cells and by PBS.Measurement of Nitrite Production.
NO production measured as nitrite concentration in stimulated cell culture supernatants was measured by the Greiss assay (15). Supernatant (100 µl) was added to 96-well plates; 100 µl of a 1:1 mixture of 1% sulfanilamide dihydrochloride in 2.5% H3PO4 and 0.1% naphthylethylenediamine dihydrochloride in 2.5% H3PO4 was then added to samples. Plates were incubated at room temperature for 10 min and A540 was determined using a microplate reader with reference to sodium nitrite standard curves. SNAP (S-nitroso- N-acetyl-penicillamine; Sigma Chemical Co.) was used as an acellular source of NO in cultures. ![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
In
studies of rmIL-12 effects in A/J mice on vaccination with
irradiated SCK tumor cells, we previously had found that
high doses of the cytokine transiently suppressed tumor
protection in vivo and proliferative responses of splenocytes
to T cell mitogens in vitro (10). We also had found that
rmIL-12 exerted similar effects (suppressed in vivo DTH
and in vitro mitogenic and alloproliferative responses) in
C57BL/6 (H-2b) mice vaccinated with irradiated allogeneic HKB (H-2a) cells. Since most effects of IL-12, both
beneficial and inhibitory, are mediated by IFN-, and because TNF-
is implicated in rmIL-12-suppressive effects
during LCMV infection (16), we examined the roles of these two cytokines in rmIL-12-induced suppression of
responses to alloimmunization. Studies using neutralizing
mAbs in C57BL/6 mice given irradiated HKB cells and a
course of rmIL-12 on days 0-4 and 7-11 showed that
XMG6 (anti-IFN-
) completely restored DTH responses,
XT22 (anti-TNF-
) only partially restored responses, and
XMG6 + XT22 restored responses no better than XMG6
alone (data not shown). Although these results suggested
that IFN-
is crucial for rmIL-12 suppression of immune
responses and that the role of TNF-
is less certain, we examined the role of these cytokines more definitively by
testing the effect of rmIL-12 on alloimmunization in mice
genetically deficient for these cytokines or their receptors. After vaccination with HKB cells, a course of rmIL-12-
suppressed DTH responses to background levels in wild-type C57BL/6 mice but had no suppressive effect in IFN-
/
C57BL/6 mice (Fig. 1 A). Similarly, rmIL-12 suppressed DTH responses in wild-type but not in IFN-
R1
/
C57BL/6 × SV129 mice vaccinated with HKB cells (data
not shown). From these results, we conclude that IFN-
is
crucial for rmIL-12-induced immunosuppression. To examine the role of TNF-
, we studied C57BL/6 × SV129
mice deficient for both the p55 and p75 TNF-
receptors. HKB-vaccinated TNFR
/
mice treated with rmIL-12
had depressed DTH responses like wild-type C57BL/6 × SV129 mice (Fig. 1 B), indicating that TNF-
responses were dispensable for rmIL-12 immune suppression. However, DTH responses without rmIL-12 were lower in the
TNFR
/
mice, suggesting that TNF-
responses might
be necessary for maximal responses.
|
In our earlier studies, suppression of in vitro splenocyte
mitogenic responses correlated well with suppression of in
vivo immune responses. This correlation held up in studies
of IFN-/
and TNFR
/
mice: Con A, IL-2, and allogeneic stimulation of splenocytes from rmIL-12-treated
IFN-
/
mice resulted in normal proliferative responses,
whereas responses of splenocytes from rmIL-12-treated
TNFR
/
mice were suppressed (data not shown).
To identify the cell population responsible for the suppressed splenocyte mitogenic responses, splenocytes from C57BL/6 mice given rmIL-12 or PBS were fractionated by adherence to plastic and reconstituted in various combinations of adherent and nonadherent cells before stimulation with Con A or IL-2. As expected, cultures of adherent and nonadherent splenocytes from rmIL-12-treated mice had suppressed mitogenic responses compared with cultures of adherent and nonadherent cells from PBS-treated mice (Fig. 2). Nonadherent cells from rmIL-12-treated mice cocultured with adherent cells from PBS-treated mice had normal mitogenic responses, indicating that mitogenesis of T cells from rmIL-12-treated mice is not intrinsically or irreversibly defective. When nonadherent cells from control mice were mixed with adherent cells from rmIL-12-treated mice, proliferative responses were severely impaired whether the stimulus was Con A, IL-2, or alloantigen (Fig. 2). These results indicate that T cells from rmIL-12-treated mice can respond to mitogens and generate an antigen-specific mitogenic response in the presence of adherent cells from normal mice, and that adherent cells are largely responsible for the defect after rmIL-12 therapy.
|
IFN- was readily detected by RIA in cocultures of adherent cells from rmIL-12-treated mice and nonadherent
cells from PBS-treated mice at both 24 and 72 h after stimulation with Con A, IL-2, or alloantigen (data not shown).
Addition of anti-IFN-
antibody to these cocultures restored mitogenic responses, whereas addition of antibodies
to IL-12, IL-10, or TNF-
had little effect (Fig. 3 A).
These antibodies did not suppress mitogenic responses in cocultures containing adherent and nonadherent splenocytes from PBS-treated mice (data not shown), indicating
that they had no intrinsic suppressive effects that could
have shrouded beneficial effects of cytokine neutralization.
These data support the results of in vivo experiments showing
a critical role for IFN-
in rmIL-12 immune suppression.
|
Knowing that adherent cells are important for
rmIL-12 suppression of in vitro mitogenic and immunological responses and that IFN- is necessary for this effect,
we considered that NO from activated macrophages might
mediate suppression. To examine this possibility, we added
an inhibitor of iNOS, L-NMMA, to cocultures of adherent
cells from rmIL-12-treated mice and nonadherent cells from control mice. We found that it reduced NO levels in
the culture supernatant by 58 and 94% in two independent
measurements and restored mitogenesis (Fig. 3 B) when
compared with addition of D-NMMA, a noninhibitory
isoform. If secreted NO is responsible for suppression of
mitogenesis, an acellular source of NO should have a similar effect. We added SNAP (S-nitroso-N-acetyl-penicillamine), an NO donor, to splenocytes from HKB-vaccinated C57BL/6 mice and found that cultures with NO
levels as low as 2.6-3.5 mM inhibited mitogenic responses
83-98%. Together, these data suggest that adherent splenocytes (probably macrophages) activated by rmIL-12 treatment to secrete NO are responsible for impaired T cell mitogenic responses.
The ability of an iNOS inhibitor to reverse rmIL-12-
induced suppression of mitogenesis in vitro suggested that
mice lacking iNOS might be resistant to the immunosuppressive effects of rmIL-12. iNOS/
and wild-type
C57BL/6 mice were vaccinated with irradiated HKB cells
and given a course of rmIL-12 or PBS. iNOS
/
mice receiving rmIL-12 had DTH responses that were at least as great as those of PBS-treated iNOS
/
and wild-type mice
and that were substantially higher than those of wild-type
mice given rmIL-12 (Fig. 4 A). Although rmIL-12 induced splenomegaly in iNOS
/
mice as in wild-type mice (17),
their splenocytes had proliferative responses like those of
splenocytes from control mice after in vitro stimulation
with mitogens or alloantigens (Fig. 4 B). Together, these data
show that macrophage-derived NO is essential for rmIL-12- induced immunosuppression, whereas rmIL-12-induced
splenomegaly and associated pathological changes are not.
|
Finding that rmIL-12 does not suppress
allogeneic responses in iNOS/
mice, we investigated
whether iNOS inhibitors would prevent immunosuppression in mice given rmIL-12 during tumor cell vaccination.
Previously, we showed that vaccinating A/J mice with irradiated SCK.GM cells was highly protective, but that administration of rmIL-12 abrogated protection 2 wk after
vaccination (but had no deleterious effect 4 wk after vaccination) (18). We gave A/J mice undergoing SCK.GM vaccination and rmIL-12 treatment either L-NAME, an
inhibitor of iNOS that acts similarly to L-NMMA, or
D-NAME, the inactive isoform. As expected, SCK.GM
vaccination protected the great majority of mice from
tumor cell challenge 2 wk after vaccination (19% developed
tumors), and rmIL-12 severely impaired this protection (94% developed tumors). L-NAME, but not D-NAME,
prevented this impairment (Fig. 5; the difference in tumorigenesis between rmIL-12-treated mice given L-NAME
versus either D-NAME or nothing is significant at P < 0.05). In mice not treated with rmIL-12, L-NAME, and
D-NAME had no effect on SCK.GM-induced protection
(data not shown), showing that L-NAME acts by preventing rmIL-12 suppression of SCK.GM vaccine efficacy.
rmIL-12 also impairs tumor protection in A/J mice with established SCK immunity if it is given just before tumor
cell rechallenge (18). We found that L-NAME but not
D-NAME given with the rmIL-12 prevented this impairment of immune rejection: only 25% of rmIL-12-treated
mice given L-NAME developed tumors, whereas 75% of
rmIL-12-treated mice given D-NAME developed tumors (data not shown). Thus, L-NAME prevents rmIL-12 suppression of established antitumor immune responses. In
these studies, levels of NO were not consistently measurable in mice given rmIL-12 (at or below the sensitivity
limits of the assay), so lower levels in mice also given
L-NAME could not be demonstrated.
|
Previously, we had shown that vaccination of A/J mice with irradiated wild-type SCK cells protected only ~10% of mice from a tumor cell challenge, i.e., SCK cells are intrinsically poorly immunogenic (18). Giving rmIL-12 with vaccination did not improve protection when mice were challenged 14 d after vaccination but did improve protection when they were challenged at 28 d. Since an iNOS inhibitor prevented transient immunosuppression by rmIL-12, we asked whether its use might reveal rmIL-12's effectiveness as a vaccine adjuvant at the earlier time point. As shown in Fig. 6, only 38% of mice given L-NAME with irradiated SCK cells and rmIL-12 developed tumors when they were challenged on day 14, whereas 75% of mice given D-NAME developed tumors. This indicated that rmIL-12 improves SCK cell vaccine efficacy markedly and rapidly but that the improvement at day 14 was obscured by rmIL-12's immunosuppressive effect. The level of protection with L-NAME at 14 d (62%) was similar to the level of protection seen at 28 d in SCK-vaccinated mice given rmIL-12 alone (75%) or rmIL-12 with L-NAME (50%) or D-NAME (50%), indicating that use of L-NAME did not impair long-term protection afforded by rmIL-12 and SCK vaccination.
|
Use of an iNOS inhibitor to alleviate rmIL-12 immune suppression would be problematic if it reduces the antitumor efficacy of the cytokine, an important consideration since the antitumor effects of rmIL-12 are diverse and some are not immunological (3, 4). Thus, we tested the effect of L-NAME on the antitumor activity of rmIL-12 against SCK tumors. Similar to what was seen in the past (19), rmIL-12 injections started on the day of SCK cell injection delayed tumor appearance by about 5 d (Fig. 7; medians of 9 d to tumor appearance without rmIL-12 and 14 d to tumor appearance with rmIL-12). Mice given L-NAME with their rmIL-12 developed tumors after a median of 17 d which was 8 d later than in untreated mice and 3 d later than in mice given rmIL-12 alone or with D-NAME. L-NAME given without rmIL-12 had no effect on SCK tumorigenesis (data not shown). Together, these data indicate that iNOS inhibitors can prevent rmIL-12 immune suppression and reveal its effectiveness as a vaccine adjuvant without adversely affecting rmIL-12 antitumor activity.
|
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
rIL-12 is a proinflammatory cytokine with potentially
useful effects against tumors and infectious agents. However, recently it has been shown to suppress cellular immune responses in mice (10). To understand the mechanisms underlying this suppression without the confounding
influence of tumor burden or host infection with pathogens, we studied the effects of rmIL-12 on allogeneic immune responses. In vivo and in vitro evidence indicates
that alloimmunization is transiently but profoundly suppressed by high-dose rmIL-12. It seems to impair immune
effector mechanisms because responses in mice with established immunity are also suppressed, and may not impair
induction of immunity because rmIL-12 given during tumor cell vaccination provides enhanced protective antitumor immunity after the period of immunosuppression.
rmIL-12 impairment of cellular immune responses is consistently associated with and likely due to impaired T cell
mitogenic responses. In this study, we provide in vivo and
in vitro evidence that anti-IFN-, but not antibodies to
other cytokines, prevents rmIL-12-induced suppression. The importance of IFN-
was confirmed by studies in
IFN-
/
and IFN-
R1
/
mice that are not immunosuppressed by rmIL-12. Studies using splenocyte fractionation,
an inhibitor of NO generation, and iNOS
/
mice revealed that adherent cells of the spleen, through stimulated production of NO by iNOS, are responsible for suppressing T cell mitogenesis in vitro and cellular immune responses in vivo. Having identified the probable mechanism, we used an iNOS inhibitor with rmIL-12 during
tumor cell vaccination that prevented immune suppression and allowed the full extent of rmIL-12 adjuvant activity to
be revealed.
These observations led us to propose that events leading
to immune suppression by high-dose rmIL-12 administration are initiated by its induction of IFN- production
by host lymphocytes. Levels of IFN-
production high
enough to activate macrophages and induce iNOS activity
generate levels of NO that impair the proliferation of T
cells in response to mitogens. That adherent cells rather than T cells are primarily responsible for the pathogenesis
of rmIL-12 immune suppression is supported by the fact
that T cells from the spleens of rmIL-12-treated mice are
normally mitogenic when cocultured with adherent cells
from normal mice or from rmIL-12-treated iNOS
/
mice.
Impairment is transient presumably because T cell proliferative responses recover as IFN-
production and consequent macrophage activation wanes after completion of
rmIL-12 therapy. How NO impairs T cell proliferative responses is uncertain, but a recent study indicates that NO
allows initial T cell activation up to and including IL-2
receptor expression and IL-2 production but impedes effective signal transduction by reversibly inhibiting JAK3
and STAT5 phosphorylation (20). Other studies have suggested that NO may induce apoptosis in conjunction with
drug therapy or infection (21, 22).
Our identification of NO as a mediator of rmIL-12-
induced immunosuppression is consistent with its known
activities. NO, a key component of host defense mechanisms against invading pathogens, is produced by iNOS
in macrophages activated by IFN- and other cytokines.
Although other NOS (nNOS or NOS1 and eNOS or
NOS3) also generate NO, iNOS (or NOS2) is the high-output source of NO, and phagocytic cells are the major
source of iNOS during inflammation (23). Impaired splenocyte mitogenesis during Salmonella typhimurium, Trypanosoma cruzi, Toxoplasma gondii, and Listeria monocytogenes infections is due to NO production associated with high
levels of IFN-
, endogenous IL-12, and/or other proinflammatory cytokines (24). When splenocytes from
these mice are fractionated, the adherent population containing macrophages and producing NO appears to suppress splenic T cell mitogenic responses, and this suppression is reversed by inhibitors of iNOS (28). Thus, diverse
processes that induce NO production by macrophages (24,
25, 29) can impair T cell proliferative responses. To this list
can be added high-dose rmIL-12 that, through induction
of high levels of IFN-
and in the absence of additional inflammatory stimuli, sufficiently activates macrophages to
engender immunosuppression.
Although NO is a mediator of impaired T cell mitogenesis, the cytokines that impair mitogenesis or induce NO
production may vary with the circumstance. In studies of
parasite infection, IFN- appears to play a significant role,
and IL-10 plays a minor role in impaired mitogenesis (30).
In studies of rmIL-12-induced immunosuppression during
LCMV infection, TNF-
has been implicated as a mediator (16). Although endogenously produced IL-12 is important for controlling Toxoplasma gondii infection, it also suppresses splenocyte mitogenic responses seen during infection (24). IL-12-directed pathways are also implicated in
immune suppression after vaccination with attenuated Salmonella typhimurium (26). These studies raise the point that
agents that naturally induce strong inflammatory responses
may engender immunosuppression through endogenous
production of proinflammatory cytokines. The specific or
spectrum of cytokines involved may vary with the initiating agent, but suppression of antigen-specific immune responses is likely to develop if the result is vigorous activation of phagocytic cells and their production of NO. In our
studies of rmIL-12-induced immune suppression, we were
only able to identify IFN-
as an essential mediator, which
may reflect the simplicity or paucity of pathways activated
by rmIL-12 compared with infectious agents. The importance of other proinflammatory cytokines for suppressing T
cell responses associated with infection and giving rmIL-12 during LCMV infection probably reflects a contribution of
these cytokines to the inflammatory response and macrophage activation under these circumstances.
Therapeutic applications of rmIL-12 may benefit from reduction or elimination of its transient immunosuppressive
side effects, and the mechanism elucidated here suggests several potential approaches. Reducing or eliminating rmIL-12
immunosuppression by using lower or fewer doses of the
cytokine is one option. Although this approach may be
beneficial (31), finding the "proper" regimen of rmIL-12 may be involved, and the results may be idiosyncratic, e.g.,
we have not found a lower dose of rmIL-12 that improves
its adjuvant effect during tumor cell vaccination (data not
shown). Inhibiting IFN- action is another alternative for
avoiding rmIL-12 immunosuppression but is an approach
that would be difficult to implement (other than in mice)
and that may be self-defeating because IFN-
may be an
essential mediator of rmIL-12 therapeutic effects. The
promising approach tested here, inhibition of NO generation, alleviates rmIL-12 immune suppression and allows its
adjuvant effects to be fully revealed. This finding suggests
that some studies testing rmIL-12 as an immunological adjuvant should be reevaluated since studies performed during the period of immune suppression are unlikely to reflect its true adjuvant potential. Of course, use of inhibitors
of NO generation in conjunction with rmIL-12 must be
examined for its independent effect on desired therapeutic endpoints. As use of the iNOS inhibitor, L-NAME, enhanced and did not impair rmIL-12's limited efficacy against
SCK tumors, our studies do not reveal any problems with its
use. Clearly, it will be important to determine whether recombinant human IL-12 produces similar immune suppressive effects in patients and, if so, whether inhibitors of iNOS
function might be beneficial in this setting.
![]() |
Footnotes |
---|
Address correspondence to William M.F. Lee, 663 Clinical Research Building, 415 Curie Blvd., University of Pennsylvania, Philadelphia, PA 19104-6140. Phone: 215-898-0258; Fax: 215-573-7912; E-mail: leemingf @
Received for publication 27 April 1998 and in revised form 10 August 1998.
We thank Genetics Institute for generously supplying the rmIL-12. We thank Dr. Cameron Koch for use of the cell irradiator, Dr. Laurence Turka for helpful discussions and generous gifts of reagents, and Dr. Philip Scott and Michelle Nashleanas (University of Pennsylvania School of Veterinary Medicine), Dr. Mark Moore (Genentech), and Dr. Horst Bluethmann (Roche Pharmaceuticals) for p55/p75 knockout mice. We thank Dr. Denise LaTemple for critical reading of the manuscript.
Supported by funds from the Department of the Army Predoctoral Training Grant DAMD17-94-J-4027 (to H.K. Koblish) and National Institutes of Health grants AI-42334-01 TMP (to C.A. Hunter), AI-34412, CA 10815, CA 20833, and CA 32898 (to G. Trinchieri), and U01 CA-65805 and R01 CA-77851 (to W.M.F. Lee).
Abbreviations used in this paper D-NAME, N-nitro-D-arginine methyl ester; D-NMMA, N-methyl-D-arginine; DTH, delayed-type hypersensitivity; iNOS, inducible nitric oxide synthase; LCMV, lymphocytic choriomeningitis virus; L-NAME, N-nitro-L-arginine methyl ester; L-NMMA, N-methyl-L-arginine; NO, nitric oxide; SCK.GM cells, SCK tumor cells engineered to secrete GM-CSF.
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1. | Brunda, M.J.. 1995. Role of IL-12 as an anti-tumor agent: current status and future directions. Res. Immunol. 146: 622-628 [Medline]. |
2. | Trinchieri, G.. 1995. Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 13: 251-276 [Medline]. |
3. | Voest, E.E., B.M. Kenyon, M.S. O'Reilly, G. Truitt, R.J. D'Amato, and J. Folkman. 1995. Inhibition of angiogenesis in vivo by interleukin-12. J. Natl. Cancer Inst. 87: 581-586 [Abstract]. |
4. |
Sgadari, C.,
A.L. Angiolillo, and
G. Tosata.
1996.
Inhibition
of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein-10.
Blood.
87:
3877-3882
|
5. |
Coughlin, C.M.,
K.E. Salhany,
M. Wysocka,
E. Aruga,
H. Kurzawa,
A.E. Chang,
C.A. Hunter,
J.C. Fox,
G. Trinchieri, and
W.M.F. Lee.
1998.
Interleukin-12 and interleukin-18
synergistically induce murine tumor regression which involves inhibition of angiogenesis.
J. Clin. Invest.
101:
1441-1452
|
6. | Atkins, M.B., M.J. Robertson, M. Gordon, M.T. Lotze, M. DeCoste, J.S. DuBois, J. Ritz, A.B. Sandler, H.D. Edington, P.D. Garzone, et al . 1997. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin. Cancer Res. 3: 409-417 [Abstract]. |
7. | Cohen, J.. 1995. IL-12 Deaths: explanation and a puzzle. Science. 270: 908-910 [Medline]. |
8. | Coughlin, C.M., M. Wysocka, G. Trinchieri, and W.M.F. Lee. 1997. The effect of interleukin-12 desensitization on the antitumor efficacy of recombinant interleukin-12. Cancer Res. 57: 2460-2467 [Abstract]. |
9. |
Orange, J.S.,
S.F. Wolf, and
C.A. Biron.
1994.
Effects of IL-12 on the response and susceptibility to experimental viral infections.
J. Immunol.
152:
1253-1264
|
10. | Kurzawa, H., M. Wysocka, E. Aruga, A.E. Chang, G. Trinchieri, and W.M.F. Lee. 1998. Interleukin 12 enhances cellular immune responses to vaccination only after a period of suppression. Cancer Res. 58: 491-499 [Abstract]. |
11. | Huang, S., W. Hendriks, A. Althage, S. Hemmi, S. Bluethmann, R. Kamijo, J. Vilhachekcek, R.M. Zinkernagel, and M. Aguet. 1993. Immune response in mice that lack the interferon-gamma receptor. Science. 259: 1742-1745 [Medline]. |
12. |
Kalb, A.,
H. Bluethmann,
M. Moore, and
W. Lesslauer.
1996.
Tumor necrosis factor receptors (Tnfr) in mouse fibroblasts deficient in Tnfr1 or Tnfr2 are signaling competent and
activate the mitogen-activated protein kinase pathway with
differential kinetics.
J. Biol. Chem.
271:
28097-28104
|
13. | Rothe, J., W. Lesslauer, H. Lotscher, Y. Lang, P. Koebel, F. Kontgen, R. Althage, R. Zinkernagel, and H. Bluethmann. 1993. Mice lacking the tumor necrosis factor receptor I are resistant to TNF-mediated cytotoxicity but highly susceptible to infection by Listeria monocytogenes. Nature. 364: 798-802 [Medline]. |
14. | Wysocka, M., M. Kubin, L.Q. Vieira, L. Ozmen, G. Garotta, P. Scott, and G. Trinchieri. 1995. Interleukin-12 is required for interferon-gamma production and lethality in lipopolysaccharide-induced shock in mice. Eur. J. Immunol. 25: 672-676 [Medline]. |
15. | Green, L.C., D.D.A. Wagner, J. Glogowski, P.L. Skepper, J.S. Wishnok, and S.R. Tannenbaum. 1982. Analysis of nitrate, nitrite and [15N]nitrate in biological fluids. Anal. Biochem. 126: 131-138 [Medline]. |
16. | Orange, J.S., T.P. Salazar-Mather, S.M. Opal, R.L. Spencer, A.H. Miller, B.S. McEwen, and C.A. Biron. 1995. Mechanism of interleukin 12-mediated toxicities during experimental viral infections: role of tumor necrosis factor and glucocorticoids. J. Exp. Med. 181: 901-914 [Abstract]. |
17. | Car, B.D., V.M. Eng, B. Schnyder, M. LeHir, A.N. Shakov, G. Woerly, S. Huang, M. Aguet, T.D. Anderson, and B. Ryffel. 1995. Role of interferon-gamma in interleukin-12- induced pathology in mice. Am. J. Pathol. 147: 1693-1707 [Abstract]. |
18. |
Rakhmilevich, A.L.,
J. Turner,
M.J. Ford,
D. McCabe,
W.H. Sun,
P.M. Sondel,
K. Grota, and
N.S. Yang.
1996.
Gene gun
mediated skin transfection with interleukin 12 genes results in
regression of established primary and metastatic murine tumors.
Proc. Natl. Acad. Sci. USA.
93:
6291-6296
|
19. | Coughlin, C.M., M. Wysocka, H. Kurzawa, W.M.F. Lee, G. Trinchieri, and S.L. Eck. 1995. B7-1 and interleukin 12 synergistically induce effective antitumor immunity. Cancer Res. 55: 4980-4987 [Abstract]. |
20. |
Bingisser, R.M.,
P.A. Tilbrook,
P.G. Holt, and
U.R. Kees.
1998.
Macrophage-derived nitric oxide regulates T cell activation via reversible disruption of the Jak3/STAT5 signaling
pathway.
J. Immunol.
160:
5729-5734
|
21. |
Singhal, P.C.,
P. Sharma,
A.A. Kapasi,
K. Reddy,
N. Franki, and
N. Gibbons.
1998.
Morphine enhances macrophage apoptosis.
J. Immunol.
160:
1886-1893
|
22. | Lopes, M.F., V.F. daVeiga, A.R. Santos, M.E.F. Fonseca, and G.A. DosReis. 1995. Activation-induced CD4+ T cell death by apoptosis in experimental Chagas' disease. J. Immunol. 154: 744-752. |
23. | MacMicking, J., Q.W. Xie, and C. Nathan. 1997. Nitric oxide and macrophage function. Annu. Rev. Immunol. 15: 323-350 [Medline]. |
24. | Hunter, C.A., E. Candolfi, C. Subauste, V. Van Cleave, and J.S. Remington. 1995. Studies on the role of interleukin-12 in acute murine toxoplasmosis. Immunology. 84: 16-20 [Medline]. |
25. |
Gregory, S.H.,
E.J. Wing,
R.A. Hoffman, and
R.L. Simmons.
1993.
Reactive nitrogen intermediates suppress the
primary immunological response to Listeria.
J. Immunol.
150:
2901-2909
|
26. | Schwacha, M.G., and T.K. Eisenstein. 1997. Interleukin-12 is critical for induction of nitric oxide-mediated immunosuppression following vaccination of mice with attenuated Salmonella typhimurium. Infect. Immun. 65: 4897-4903 [Abstract]. |
27. |
Fernandez-Gomez, R.,
S. Esteban,
R. Gomez-Corvera,
K. Zoulika, and
A. Ouaissi.
1998.
Trypanasoma cruzi: Tc52 released protein-induced increased expression of nitric oxide
synthase and nitric oxide production by macrophages.
J. Immunol.
160:
3471-3479
|
28. | Candolfi, E., C.A. Hunter, J.S. Remington, and R.C. Mulligan. 1994. Mitogen- and antigen-specific proliferation of T cells in murine toxoplasmosis is inhibited by reactive nitrogen intermediates. Infect. Immun. 62: 1995-2001 [Abstract]. |
29. |
Fecho, K.,
K.A. Maslonek,
M.E. Coussens-Read,
L.A. Dykstra, and
D.T. Lysle.
1994.
Macrophage-derived nitric oxide
is involved in the depressed concanavalin A responsiveness of
splenic lymphocytes from rats administered morphine in
vivo.
J. Immunol.
152:
5845-5852
|
30. | Candolfi, E., C.A. Hunter, and J.S. Remington. 1995. Roles of gamma interferon and other cytokines in suppression of the spleen cell proliferative response to concanavalin A and toxoplasma antigen during acute toxoplasmosis. Infect. Immun. 63: 751-756 [Abstract]. |
31. | Noguchi, Y., E.C. Richards, Y.-T. Chen, and L.J. Old. 1995. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc. Natl. Acad. Sci. USA. 92: 2219-2223 [Abstract]. |